Publications

Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis.

Jha, S; Ismail, N; Clark, D; LEWIS, JJ; Omar, S; Dreyer, A; Chihota, V; CHURCHYARD, G; Dowdy, DW;

2016

PloS one, (2016).11 6 10.1371/journal.pone.0157554.

The global diabetes epidemic: what does it mean for infectious diseases in tropical countries?.

Van Crevel, R; Van de Vijver, S; MOORE, DA J;

2016

The lancet Diabetes & endocrinology, (2016).5 6 10.1016/S2213-8587(16)30081-X.

The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance.

Gehre, F; Otu, J; Kendall, L; Forson, A; Kwara, A; Kudzawu, S; Kehinde, AO; Adebiyi, O; Salako, K; Baldeh, I; Jallow, A; Jallow, M; Dagnra, A; Dissé, K; Kadanga, EA; Idigbe, EO; Onubogu, C; Onyejepu, N; Gaye-Diallo, A; Ba-Diallo, A; Rabna, P; Mane, M; Sanogo, M; Diarra, B; Dezemon, Z; ... ANTONIO, M.

2016

BMC medicine, (2016).14 1 10.1186/s12916-016-0704-5.

The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study.

Hermans, SM; GRANT, AD; Chihota, V; LEWIS, JJ; VYNNYCKY, E; CHURCHYARD, GJ; FIELDING, KL;

2016

BMC medicine, (2016).14 1 10.1186/s12916-016-0589-3.

Transcriptional Profiling of Mycobacterium tuberculosis Exposed to In Vitro Lysosomal Stress.

Lin, W; De Sessions, PF; Teoh, GH K; Mohamed, AN N; Zhu, YO; Koh, VH Q; Ang, ML T; Dedon, PC; HIBBERD, ML; Alonso, S;

2016

Infection and immunity, (2016).84 9 10.1128/IAI.00072-16.

The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions.

RHODES, SJ; ZELMER, A; KNIGHT, GM; PRABOWO, SA; STOCKDALE, L; Evans, TG; Lindenstrøm, T; WHITE, RG; FLETCHER, H;

2016

Vaccine, (2016).34 50 10.1016/j.vaccine.2016.10.060.

Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance.

PHELAN, J; COLL, F; McNerney, R; Ascher, DB; Pires, DE V; FURNHAM, N; Coeck, N; Hill-Cawthorne, GA; Nair, MB; Mallard, K; Ramsay, A; CAMPINO, S; HIBBERD, ML; Pain, A; Rigouts, L; CLARK, TG;

2016

BMC medicine, (2016).14 1 10.1186/s12916-016-0575-9.

Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease.

Awoniyi, DO; Teuchert, A; SUTHERLAND, JS; Mayanja-Kizza, H; Howe, R; Mihret, A; Loxton, AG; Sheehama, J; Kassa, D; CRAMPIN, AC; DOCKRELL, HM; Kidd, M; Rosenkrands, I; Geluk, A; Ottenhoff, TH M; Corstjens, PL A M; Chegou, NN; Walzl, G; AE-TBC Consortium,;

2016

The Journal of infection, (2016).73 3 10.1016/j.jinf.2016.04.036.

Cohort Profile: The Kilifi Vaccine Monitoring Study.

ADETIFA, IM O; Bwanaali, T; Wafula, J; Mutuku, A; Karia, B; Makumi, A; Mwatsuma, P; Bauni, E; Hammitt, LL; Nokes, DJ; Maree, E; Tabu, C; Kamau, T; Mataza, C; Williams, TN; SCOTT, JA G;

2016

International journal of epidemiology, (2016).46 3 10.1093/ije/dyw202.

End TB strategy: the need to reduce risk inequalities.

Gomes, MG M; Barreto, ML; Glaziou, P; MEDLEY, GF; RODRIGUES, LC; Wallinga, J; Squire, SB;

2016

BMC infectious diseases, (2016).16 1 10.1186/s12879-016-1464-8.